Alignment Healthcare (NASDAQ:ALHC) Given Overweight Rating at Stephens

Stephens restated their overweight rating on shares of Alignment Healthcare (NASDAQ:ALHC - Free Report) in a research report report published on Monday morning,Benzinga reports. They currently have a $17.00 price target on the stock.

ALHC has been the topic of a number of other reports. Barclays increased their target price on shares of Alignment Healthcare from $7.00 to $8.00 and gave the stock an "underweight" rating in a report on Wednesday, October 30th. Stifel Nicolaus increased their price objective on shares of Alignment Healthcare from $14.00 to $16.00 and gave the stock a "buy" rating in a research note on Tuesday, January 14th. Finally, UBS Group lifted their target price on Alignment Healthcare from $9.00 to $12.00 and gave the company a "neutral" rating in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $11.88.

Alignment Healthcare Stock Up 2.4 %

NASDAQ:ALHC traded up $0.31 during mid-day trading on Monday, reaching $13.47. The stock had a trading volume of 1,238,519 shares, compared to its average volume of 1,867,735. The company has a debt-to-equity ratio of 1.82, a current ratio of 1.60 and a quick ratio of 1.60. The company has a market capitalization of $2.58 billion, a price-to-earnings ratio of -17.49 and a beta of 1.50. Alignment Healthcare has a 1-year low of $4.46 and a 1-year high of $15.82. The stock's 50 day simple moving average is $13.34 and its two-hundred day simple moving average is $11.88.

Remove Ads

Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. Alignment Healthcare had a negative return on equity of 108.69% and a negative net margin of 5.84%. Equities analysts anticipate that Alignment Healthcare will post -0.69 EPS for the current year.

Insider Transactions at Alignment Healthcare

In related news, CEO John E. Kao sold 90,000 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $11.65, for a total value of $1,048,500.00. Following the completion of the transaction, the chief executive officer now owns 2,363,100 shares in the company, valued at $27,530,115. This represents a 3.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Andreas P. Wagner sold 14,878 shares of the firm's stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $14.38, for a total transaction of $213,945.64. Following the transaction, the insider now directly owns 200,885 shares in the company, valued at approximately $2,888,726.30. The trade was a 6.90 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 441,002 shares of company stock worth $5,772,726. Company insiders own 6.60% of the company's stock.

Institutional Investors Weigh In On Alignment Healthcare

A number of institutional investors have recently added to or reduced their stakes in ALHC. Creative Planning increased its position in shares of Alignment Healthcare by 20.0% during the 3rd quarter. Creative Planning now owns 12,442 shares of the company's stock valued at $147,000 after purchasing an additional 2,072 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Alignment Healthcare by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,963 shares of the company's stock worth $641,000 after acquiring an additional 2,154 shares during the period. Rhumbline Advisers raised its position in Alignment Healthcare by 2.2% in the fourth quarter. Rhumbline Advisers now owns 135,704 shares of the company's stock worth $1,527,000 after acquiring an additional 2,937 shares in the last quarter. MetLife Investment Management LLC raised its position in Alignment Healthcare by 5.6% in the fourth quarter. MetLife Investment Management LLC now owns 61,344 shares of the company's stock worth $690,000 after acquiring an additional 3,256 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in Alignment Healthcare by 2.8% in the 4th quarter. Alliancebernstein L.P. now owns 119,440 shares of the company's stock valued at $1,344,000 after acquiring an additional 3,300 shares during the last quarter. 86.19% of the stock is currently owned by institutional investors and hedge funds.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.